Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Share News (COG)

Share Price Information for Cambridge Cog (COG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 45.00
Bid: 44.00
Ask: 46.00
Change: 0.00 (0.00%)
Spread: 2.00 (4.545%)
Open: 45.00
High: 45.00
Low: 45.00
Prev. Close: 45.00
COG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Forbidden Technologies Up On Microsoft Deal

Wed, 16th Mar 2016 10:33

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.
----------
FTSE 100 - LOSERS
----------
Smiths Group, down 2.3%. The engineer said pretax profit rose in the first half thanks to better operating margins, though its John Crane business continues to suffer amid the tough oil and gas markets. The diversified engineer, which will be demoted from the FTSE 100 next week, said pretax profit for the six months to the end of July was GBP168.0 million, up from GBP131.0 million a year earlier. Revenue fell to GBP1.37 billion from GBP1.42 billion, but the group's operating margin improved to 13.3% from 11.6%. Smiths said it will pay an interim dividend of 13.25 pence per share, up from 13.00p a year earlier.

Hikma Pharmaceuticals, down 1.7%. The pharmaceuticals company, which will be demoted to the FTSE 250 next week, reported a fall in pretax profit in 2015, but forecast a significant rise in revenue for the year ahead, helped by its recent acquisition of the Roxane Laboratories, despite lowering its guidance for the Roxane business last month. The company reported a pretax profit of USD318 million, down from USD362 million in 2014, as revenue slipped to USD1.44 billion from USD1.49 billion the year before. Hikma proposed a final dividend of 21 cents per share, taking its total dividend to 32 cents for the year, in line with what it paid in 2014.
----------
FTSE 250 - WINNERS
----------
Tullow Oil, up 4.1%. The oil and gas company said it has encountered "good oil shows" across an interval of over 700 metres in the Cheptuket-1 well in Block12A in northern Kenya. The well is the first one to test the Kerio Valley Basin and was drilled by the PR Marriott Rig-46 to a final depth of 3,083 metres.

Greggs, up 1.5%. The food-to-go retailer was upgraded to Hold from Sell by Berenberg.
----------
FTSE 250 - LOSERS
----------
Thomas Cook Group, down 6.4%. The travel company was downgraded to Sell from Neutral by Citi.

Moneysupermarket.com Group, down 4.5%. The price comparison site's founder Simon Nixon has completed the sale of his entire remaining stake in the company, according to sole bookrunner Credit Suisse. Credit Suisse Securities placed 37.8 million shares on behalf of Nixon at 328.00 pence per share, raising a total of GBP124.0 million. The shares sold represent around 6.9% of the company's issued share capital. Moneysupermarket shares closed at 343.6p on Tuesday and were quoted at 328.20p Wednesday. The intended sale was announced soon after the market close Tuesday.
----------
MAIN MARKET AND AIM - WINNERS
----------
Forbidden Technologies, up 33%. The cloud-based video technology group said it has signed a deal with US technology giant Microsoft Corp for it Forscene cloud video platform. Under the deal, Microsoft will be able to sell the Forscene platform through its Azure cloud computing marketplace. "Not only is this agreement a further validation of the efficacy of our technology, it's an important milestone as we further expand our sales apparatus. Whilst we expect to generate some income directly from this agreement in 2016, we anticipate its financial impact being most acutely seen from 2017," said Aziz Musa, Forbidden's chief executive.

Kainos Group, up 4.7%. The software services company said trading remains in line with its expectations, with some signs of improvement in conditions in the public sector market. Kainos said a gradual brightening of conditions in the UK public sector market should drive further opportunities on its contracts with the Ministry of Justice and the Office of National Statistics. Kainos also remains optimistic on potential opportunities from the ongoing digitisation of the UK's National Health Service and said it is well positioned to benefit when work arises. Kainos also signed a partnership with InTouch Health, a telehealth services company, with the deal focused on Kainos's Evolve unit boosting InTouch's mobile capabilities.
----------
MAIN MARKET AND AIM - LOSERS
----------
Cambridge Cognition Holdings, down 16%. The neuropsychological tests developer said it is expecting net loss of GBP800,000 in its 2015 results, after a delay to one of the three clinical trial contracts announced in November. Cambridge Cognition said in November it had won three pharmaceutical clinical trial contracts totalling USD4.5 million with upfront payments and revenues to be recognised through to 2017. It said it expected trial initial revenue for the trials in its 2015 results. However, the group said the pharmaceutical partner for one of the three studies informed the company of delays in initiating the planned clinical study due to regulatory reviews, resulting in the revenue shifting to 2016.

Wandisco, down 16%. The Big Data company said reduced costs resulted in a narrowed loss in 2015, though revenue edged lower. WANdisco said its pretax loss for the year to the end of December narrowed to USD31.0 million from USD39.4 million a year earlier, despite revenue slipping slightly to USD11.0 million from USD11.2 million. The narrowed loss resulted from a lower cost of sales and fewer operating expenses.

Tribal Group, down 6.6% at 40.50 pence. The education software group announced a discounted rights issue to shore up its financial position as its loss for 2015 widened significantly. Tribal said it will raise GBP21.0 million through a fully-underwritten rights issue in order to reduce its debt pile. It will issue 94.8 million shares at 22.00p per share to raise the funds. The move came as the group's pretax loss for the year to the end of December widened to GBP47.3 million from a GBP6.3 million loss a year earlier, primarily due to impairment charges as it restructured its operations.
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
15 Jul 2020 16:20

Cambridge Cognition joins Covid healthcare worker investigation

(Sharecast News) - Cambridge Cognition is collaborating with 4YouandMe and the Center for International Emergency Medical Services (CIEMS), it announced on Wednesday, to investigate the use of wearables and mobile phones to measure stress recovery in front line healthcare workers caring for Covid-19 positive patients in the United States.

Read more
15 Jul 2020 11:47

UK TRADING UPDATE SUMMARY: Finsbury Food's Annual Revenue Set To Fall

UK TRADING UPDATE SUMMARY: Finsbury Food's Annual Revenue Set To Fall

Read more
30 Jun 2020 20:26

IN BRIEF: Cambridge Cognition Interim Order Intake Surges Annually

IN BRIEF: Cambridge Cognition Interim Order Intake Surges Annually

Read more
30 Jun 2020 11:00

Cambridge Cognition order intake nearly doubles in H1

(Sharecast News) - Software group Cambridge Cognition has seen its order intake almost double in the six months ended 30 June following the company's switch in focus to having a more diversified portfolio and its efforts to commercialise new products.

Read more
27 May 2020 13:10

UK TRADING UPDATE SUMMARY: Caffyns To Reopen Showrooms As Curbs Ease

UK TRADING UPDATE SUMMARY: Caffyns To Reopen Showrooms As Curbs Ease

Read more
27 May 2020 10:08

Cambridge Cognition inks multiple new contracts for virtual trials

(Sharecast News) - Digital brain health products developer Cambridge Cognition has secured several new contracts to support pharmaceutical clients in delivering virtual clinical trials, including two contracts collectively worth over £1m.

Read more
5 May 2020 12:11

Cambridge Cognition 2019 Loss Widens As Revenue Falls On Sales Decline

Cambridge Cognition 2019 Loss Widens As Revenue Falls On Sales Decline

Read more
17 Mar 2020 16:03

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
17 Mar 2020 16:02

Cambridge Cognition Three Contracts Worth Total Of GBP1.4 Million

Cambridge Cognition Three Contracts Worth Total Of GBP1.4 Million

Read more
2 Mar 2020 16:00

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
19 Feb 2020 09:40

Cambridge Cognition To Raise GBP1.4 Million; Expects Wider Annual Loss

Cambridge Cognition To Raise GBP1.4 Million; Expects Wider Annual Loss

Read more
19 Feb 2020 08:03

Cambridge Cognition losses widen amid sales slump

(Sharecast News) - Digital solutions development group Cambridge Cognition warned on Wednesday that its full-year losses were set to widen after the lower level of sales seen throughout the first half of the year extended into the third quarter

Read more
25 Nov 2019 09:36

Cambridge Cognition gains client with improved electronic assessment platform

(Sharecast News) - Brain health solutions developer Cambridge Cognition Holdings announced the launch of an improved electronic clinical outcomes assessment ('eCOA') platform on Monday, claiming it had already attracted a new client from one of the world's top 10 pharmaceutical companies.

Read more
25 Oct 2019 15:22

Cambridge Cognition hoping to ride coat-tails of Biogen Alzheimer's programme

(Sharecast News) - Cambridge Cognition announced on Friday that, Following a consultation with the US Food and Drug Administration (FDA), Biogen and Eisai have announced plans to pursue regulatory approval for 'aducanumab', which would be the first therapy to tackle clinical decline in early Alzheimer's disease.

Read more
25 Oct 2019 10:37

Cambridge Cognition Senses Opportunity In Biogen's Alzheimer Drug Push

Cambridge Cognition Senses Opportunity In Biogen's Alzheimer Drug Push

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.